⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423980 | 0.78 | — | — | |
| SCHEMBL9418096 | 0.78 | — | — | |
| SCHEMBL10204018 | 0.73 | — | — | |
| SCHEMBL15030109 | 0.71 | — | — | |
| SCHEMBL18072942 | 0.69 | — | — | |
| SCHEMBL27713814 | 0.67 | — | — | |
| SCHEMBL18828543 | 0.67 | — | — | |
| SCHEMBL13384114 | 0.67 | — | — | |
| SCHEMBL16790337 | 0.65 | — | — | |
| SCHEMBL12652764 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3359154-B1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2021-05-26 | — | — | EP | disclosed |
| EP-3575298-A1 | FUSED HETEROCYCLIC COMPOUND AND COMPOSITION CONTAINING SAME | Sumitomo Chemical Company Limited (JP) | 2019-12-04 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2017062688-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2017-04-13 | — | — | WO | disclosed |
| US-20160116448-A1 | pH-MODULATED QUENCHERS OF FLUORESCENCE | BERRY AND ASSOCIATES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9150582-B2 | Composition and method for neuropeptide S receptor (NPSR) antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |